Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Alemtuzumab and multiple sclerosis: therapeutic application.
Alemtuzumab for the Treatment of Multiple Sclerosis
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Interferon-β-1b: a review of its use in multiple sclerosis.
Rituximab product approval information - Licensing action
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Adaptive myelination from fish to man.
Ethnicity and prevalence of multiple sclerosis in east London.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Biogen Idec completes purchase of full rights and control of Tysabri®

Pages